1 – 20 of 20
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases : consensus statements from the ERA-IWG and EUVAS
(
- Contribution to journal › Scientific review
-
Mark
The Sound of Interconnectivity; The European Vasculitis Society 2022 Report
(
- Contribution to journal › Article
- 2020
-
Mark
Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis
(
- Contribution to journal › Article
- 2017
-
Mark
The European Vasculitis Society 2016 Meeting Report
(
- Contribution to journal › Article
-
Mark
Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts
(
- Contribution to journal › Article
-
Mark
Severe infection in antineutrophil cytoplasmic antibody-associated vasculitis
(
- Contribution to journal › Article
- 2016
-
Mark
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
(
- Contribution to journal › Article
- 2015
-
Mark
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
(
- Contribution to journal › Article
-
Mark
Outcome and Treatment of Elderly Patients with ANCA-Associated Vasculitis.
(
- Contribution to journal › Article
-
Mark
NT-rådets ställningstagande till eculizumab är oacceptabelt
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Slutreplik, Diana Karpman och medförfattare : - NT-rådet bör omedelbart återkalla sitt beslut om eculizumab
(
- Contribution to journal › Debate/Note/Editorial
- 2010
-
Mark
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis.
(
- Contribution to journal › Article
- 2009
-
Mark
Randomized trial of rituximab vs cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS
(
- Contribution to journal › Published meeting abstract
-
Mark
Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa.
(
- Contribution to journal › Article
- 2008
-
Mark
The incidence of renal vasculitis in southern Sweden
2008) 72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals In Arthritis and Rheumatism 58(9). p.848-848(
- Contribution to journal › Published meeting abstract
- 2007
-
Mark
På väg mot evidensbaserad terapi vid primär systemisk vaskulit. De senaste decenniernas framsteg har gett dagens patienter bättre läge
(
- Contribution to journal › Article
- 2006
-
Mark
Increased neutrophil membrane expression and plasma level of proteinase 3 in systemic vasculitis are not a consequence of the - 564 A/G promotor polymorphism.
(
- Contribution to journal › Article
- 1999
-
Mark
Recurrent ANCA-associated small vessel vasculitis after transplantation : A pooled analysis
(
- Contribution to journal › Article
-
Mark
C3 and C4 allotypes in anti-neutrophil cytoplasmic autoantibody (ANCA)- positive vasculitis
(
- Contribution to journal › Article
- 1998
-
Mark
Clinical evaluation of a capture ELISA for detection of proteinase-3 antineutrophil cytoplasmic antibody : Technical note
(
- Contribution to journal › Article